← The Wire
REGNNasdaq
REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · NY · CIK 872589
Regeneron Pharmaceuticals discovers, develops, and commercializes medicines for serious diseases
⚡ Elevated coverage
$64.18B
Market cap
$631.81
Last close
-0.2%
1D
+3.1%
5D
734K
Volume
Price · last 39 sessions-10.9%
May 4L $600.66 · H $723.41Jun 29
165
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 24, 2026DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 29, 2025DEFA14AREGENERON PHARMACEUTICALS, INC. - DEFA14AApr 25, 2024DEFA14ADEFA14AMay 17, 2023DEFA14AREGENERON PHARMACEUTICALS, INC. - DEFA14AApr 21, 2023DEFA14ADEFA14AApr 21, 2022DEFA14ADEFA14AApr 21, 2022DEFA14ADEFA14AMay 3, 2021DEFA14ADEFA14AApr 23, 2021DEFA14ADEFA14AApr 23, 2021DEFA14ADEFA14AJun 8, 2020DEFA14ADEFA14AApr 24, 2020DEFA14ADEFA14AApr 24, 2020DEFA14ADEFA14AApr 26, 2019DEFA14ADEFA14AApr 26, 2019DEFA14ADEFA14AApr 23, 2018DEFA14ADEFA14AApr 23, 2018DEFA14ADEFA14AApr 25, 2017DEFA14ADEFA14AApr 25, 2017
Insider Activity
In the 90 days to Mar 2, 2026: 4 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $789.28 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $788.96 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 11 | $785.48 | $9K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 10 | $783.62 | $8K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 9 | $784.48 | $7K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $786.61 | $6K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $777.46 | $5K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 5 | $779.69 | $4K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 3 | $780.69 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $787.34 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $782.62 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $781.21 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $778.30 | $2K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 331 | $780.45 | $258K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 298 | $782.10 | $233K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 220 | $783.29 | $172K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 209 | $781.28 | $163K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 208 | $779.55 | $162K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 160 | $784.45 | $126K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 56 | $785.61 | $44K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 5 reputable articles · skews – neutral.
MarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day12d agoMarketWatchRegeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market18d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors21d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains24d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains25d agoMarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance